R&D | December 07, 2025
Bayer advances fight against rare kidney disease with new experimental drug
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
It's an acquisition that aims at forming one of the US's largest oncology trial networks
MRI is particularly valuable in pediatric care due to its non-invasive nature
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
Siponimod Tablets is indicated for the treatment of relapsing forms of multiple sclerosis
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
